While the news isn’t great for vaccine manufacturers, it could have been worse. Shares of pure vaccine play Moderna rose 0.3% ...

While Pfizer said in its petition for mass tort designation that it expected many of the dismissed plaintiffs to refile their ...

Pfizer CEO Albert Bourla, Ph.D., has pulled back the curtain on his $1.25 billion bet on a PD-1xVEGF bispecific, revealing ...

Pfizer jumps into cancer-treatment race with a $6 billion licensing deal with a China-based company, six months after Merck’s move for a lot less money.

Pharmaceutical rivals don’t often come to each other’s defense. But after the US Department of Health and Human Services ...

Pfizer and other drug companies have met with the Trump administration to discuss lowering U.S. drug prices but no ...

Despite recent declines, we believe Pfizer stock is a compelling buy right now, with its current price of around $23 likely ...

Science came to life as curious young minds took center stage at the Pfizer School of Science Mobile Experience, a hands-on ...

Pfizer's CEO discussed the extensive due diligence the company has conducted on the 3SBio PD-1xVEGF deal. | Pfizer's CEO ...

Recipients of the Pfizer mRNA vaccine experienced more all-cause deaths within the first 100 days post-vaccination than ...

Pfizer offers a high 7.4% dividend yield and trades at low valuation multiples. Click here to read more about PFE stock and ...

Its dividend: The stock recently yielded a whopping 7.3%. That's hard to beat and will generate around $730 for every $10,000 ...